
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is experiencing top-line and bottom-line misses in recent quarters due to weak performance of its flagship product, Baqsimi, which is facing intense pricing pressure and higher pharmacy discounts. Despite taking measures like a recent price increase, Baqsimi sales are expected to remain flat or grow only marginally, leading to a revision of sales growth expectations for the year. Additionally, the company's overall revenue growth for 2026 is expected to be in the mid to high-single digits.
Bears say
Amphastar Pharma is facing several challenges, including pricing headwinds and competitive headwinds in the generics business. Despite having a strong pipeline with potential growth opportunities, the visibility of when these opportunities will materialize is unclear, leading to uncertainty about top-line and EBITDA growth. With Baqsimi sales declining, potential new product launches not expected until 2027, and the company's future success dependent on pipeline development, it is clear why the analyst has a negative outlook on Amphastar Pharma's stock.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares